Functionalised Cardiovascular Stents
302,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
151 °P sammeln
  • Gebundenes Buch

Cardiovascular disease is a major cause of mortality in the western world and about half of these deaths are caused by coronary artery disease. One of the most commonly used interventions to treat arterial blockages is to deploy an arterial stent to keep the vessel open. Traditionally, some cardiovascular stents have been associated with serious side-effects, such as thrombosis.
This book describes the fundamentals of cardiovascular stents, technologies to functionalize their surfaces and the market status of these important implants. The chapters provide specific focus on the production…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Cardiovascular disease is a major cause of mortality in the western world and about half of these deaths are caused by coronary artery disease. One of the most commonly used interventions to treat arterial blockages is to deploy an arterial stent to keep the vessel open. Traditionally, some cardiovascular stents have been associated with serious side-effects, such as thrombosis.

This book describes the fundamentals of cardiovascular stents, technologies to functionalize their surfaces and the market status of these important implants. The chapters provide specific focus on the production and evolution of cardiovascular stents, providing essential knowledge for researchers on advances in the field and knowledge of how cardiovascular stents are currently being "functionalized" in order to improve their biocompatibility and minimize negative outcomes in vivo.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Gerard Wall obtained his primary degree in Microbiology from the National University of Ireland, Galway, followed by a PhD in Molecular Immunology from the University of Aberdeen, Scotland. After a period spent engineering antibodies at the University of Zurich in Switzerland, he established his own research group in protein engineering at the University of Limerick, Ireland. He returned to NUI Galway in 2008 and is based in Microbiology and the Centre for Research in Medical Devices (CÚRAM). He has published widely on recombinant protein expression and engineering and has particular interests in the fields of antibody engineering, drug delivery, and materials functionalization.

Dr. Magdalena Wawrzyn ´ska is an interventional cardiologist and internal medicine specialist, a member of European Society of Cardiology and the European Association of Percutaneous Interventions. She obtained her M.D. degree, followed by PhD in Internal Diseases at Wroclaw Medical University, Poland, and is currently an academic teacher at Wroclaw Medical University and practitioning clinitian Her research focus is experimental cardiology and diagnosis and advanced treatment of coronary artery diseases. She has been awarded a silver medal at the International Exhibition of Innovation, Entrepreneurship and New Technologies, Eureka Brussels in 2006 and bronze medal at the Concours Lepine International Paris in 2016. Dr Wawrzyn ´ska is the owner of several patent applications in the field of innovative solutions for cardiology.